Eli Lilly's late-phase trials SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN show that adults with obesity maintained most of their weight loss after switching from high doses of injectable therapies Wegovy and Zepbound to either oral Foundayo or lower-dose Zepbound. Participants who continued Zepbound at maximum tolerated doses maintained all prior weight loss, while those who switched to Foundayo or reduced Zepbound doses maintained nearly all weight loss after one year. These findings highlight the potential for durable weight management using oral and injectable GLP-1 therapies, addressing the challenge of weight regain in obesity care. Both drugs showed safety profiles consistent with previous studies, supporting their use for long-term obesity treatment.
Nvidia's market capitalization recently exceeded $5.3 trillion, surpassing the combined value of all 59 healthcare companies in the S&P 500, which total about $5.2 trillion. This shift highlights the massive investor confidence in AI infrastructure, ...
Eli Lilly launched a charitable initiative supporting community organizations to distribute 500,000 nutritious meals across 15 U.S. communities as part of its 150th anniversary. The company also funds cold storage infrastructure for 150 food pantries...
Eli Lilly reported a strong Q1 2026 with revenue up 55.5% to $19.8 billion and earnings per share beating estimates. Its drug Mounjaro became the world's top-selling medication, driving optimism and a raised full-year revenue forecast of $82-$85 bill...
Eli Lilly's stock surged after a strong Q1 report with revenue up 55.55% year-over-year and raised full-year guidance, yet it remains down 10% year-to-date. The company’s GLP-1 drugs Mounjaro and Zepbound showed significant growth, but pricing pressu...
Eli Lilly reported a strong Q1 2026 with 55.55% revenue growth to $19.8 billion, driven by blockbuster drugs Mounjaro and Zepbound, and raised its full-year revenue guidance. The company is investing aggressively in AI drug discovery and acquisitions...
